Lachlan R Gray1, Michael Roche, Jacqueline K Flynn, Steve L Wesselingh, Paul R Gorry, Melissa J Churchill. 1. aCentre for Biomedical Research, Burnet Institute bDepartment of Infectious Diseases, Monash University, Melbourne, Victoria cSouth Australian Health and Medical Research Institute, Adelaide, South Australia dDepartment of Microbiology and Immunology, University of Melbourne, Parkville eDepartment of Microbiology, Monash University, Clayton fDepartment of Medicine, Monash University, Melbourne, Victoria, Australia.
Abstract
PURPOSE OF REVIEW: To summarize the evidence in the literature that supports the central nervous system (CNS) as a viral reservoir for HIV-1 and to prioritize future research efforts. RECENT FINDINGS: HIV-1 DNA has been detected in brain tissue of patients with undetectable viral load or neurocognitive disorders, and is associated with long-lived cells such as astrocytes and microglia. In neurocognitively normal patients, HIV-1 can be found at high frequency in these cells (4% of astrocytes and 20% of macrophages). CNS cells have unique molecular mechanisms to suppress viral replication and induce latency, which include increased expression of dominant negative transcription factors and suppressive epigenetic factors. There is also evidence of continued inflammation in patients lacking a CNS viral load, suggesting the production and activity of viral neurotoxins (for example, Tat). SUMMARY: Together, these findings provide evidence that the CNS can potentially act as a viral reservoir of HIV-1. However, the majority of these studies were performed in historical cohorts (absence of combination antiretroviral therapy or presence of viral load), which do not reflect modern day patients (combination antiretroviral therapy-treated and undetectable viral load). Future studies will need to examine patient samples with these characteristics to conclusively determine whether the CNS represents a relevant and important viral reservoir.
PURPOSE OF REVIEW: To summarize the evidence in the literature that supports the central nervous system (CNS) as a viral reservoir for HIV-1 and to prioritize future research efforts. RECENT FINDINGS:HIV-1 DNA has been detected in brain tissue of patients with undetectable viral load or neurocognitive disorders, and is associated with long-lived cells such as astrocytes and microglia. In neurocognitively normal patients, HIV-1 can be found at high frequency in these cells (4% of astrocytes and 20% of macrophages). CNS cells have unique molecular mechanisms to suppress viral replication and induce latency, which include increased expression of dominant negative transcription factors and suppressive epigenetic factors. There is also evidence of continued inflammation in patients lacking a CNS viral load, suggesting the production and activity of viral neurotoxins (for example, Tat). SUMMARY: Together, these findings provide evidence that the CNS can potentially act as a viral reservoir of HIV-1. However, the majority of these studies were performed in historical cohorts (absence of combination antiretroviral therapy or presence of viral load), which do not reflect modern day patients (combination antiretroviral therapy-treated and undetectable viral load). Future studies will need to examine patient samples with these characteristics to conclusively determine whether the CNS represents a relevant and important viral reservoir.
Authors: Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano Journal: Nat Med Date: 2003-05-18 Impact factor: 53.440
Authors: Daniele Marras; Leslie A Bruggeman; Feng Gao; Nozomu Tanji; Mahesh M Mansukhani; Andrea Cara; Michael D Ross; G Luca Gusella; Gary Benson; Vivette D D'Agati; Beatrice H Hahn; Mary E Klotman; Paul E Klotman Journal: Nat Med Date: 2002-05 Impact factor: 53.440
Authors: M C Zink; K Suryanarayana; J L Mankowski; A Shen; M Piatak; J P Spelman; D L Carter; R J Adams; J D Lifson; J E Clements Journal: J Virol Date: 1999-12 Impact factor: 5.103
Authors: Suzanne E Queen; Brian M Mears; Kathleen M Kelly; Jamie L Dorsey; Zhaohao Liao; Jason B Dinoso; Lucio Gama; Robert J Adams; M Christine Zink; Janice E Clements; Stephen J Kent; Joseph L Mankowski Journal: J Virol Date: 2011-06-29 Impact factor: 5.103
Authors: B A Watkins; H H Dorn; W B Kelly; R C Armstrong; B J Potts; F Michaels; C V Kufta; M Dubois-Dalcq Journal: Science Date: 1990-08-03 Impact factor: 47.728
Authors: Paul R Gorry; Chi Ong; Janine Thorpe; Sylvie Bannwarth; Katherine A Thompson; Anne Gatignol; Steven L Vesselingh; Damian F J Purcell Journal: Curr HIV Res Date: 2003-10 Impact factor: 1.581
Authors: Serena Spudich; Kevin R Robertson; Ronald J Bosch; Rajesh T Gandhi; Joshua C Cyktor; Hanna Mar; Bernard J Macatangay; Christina M Lalama; Charles Rinaldo; Ann C Collier; Catherine Godfrey; Joseph J Eron; Deborah McMahon; Jana L Jacobs; Dianna Koontz; Evelyn Hogg; Alyssa Vecchio; John W Mellors Journal: J Clin Invest Date: 2019-07-15 Impact factor: 14.808
Authors: Irma E Cisneros; Mert Erdenizmenli; Kathryn A Cunningham; Slobodan Paessler; Kelly T Dineley Journal: Neuropharmacology Date: 2018-03-23 Impact factor: 5.250
Authors: Lachlan R Gray; Hung On; Emma Roberts; Hao K Lu; Michael A Moso; Jacqueline A Raison; Catherine Papaioannou; Wan-Jung Cheng; Anne M Ellett; Jonathan C Jacobson; Damian F J Purcell; Steve L Wesselingh; Paul R Gorry; Sharon R Lewin; Melissa J Churchill Journal: J Neurovirol Date: 2016-01-04 Impact factor: 2.643
Authors: Ajay Singh; Hilliard L Kutscher; Julia C Bulmahn; Supriya D Mahajan; Guang S He; Paras N Prasad Journal: Nanomedicine Date: 2020-02-13 Impact factor: 5.307
Authors: Maria M Bednar; Christa Buckheit Sturdevant; Lauren A Tompkins; Kathryn Twigg Arrildt; Elena Dukhovlinova; Laura P Kincer; Ronald Swanstrom Journal: Curr HIV/AIDS Rep Date: 2015-06 Impact factor: 5.071
Authors: Lee A Campbell; Christopher T Richie; Yajun Zhang; Emily J Heathward; Lamarque M Coke; Emily Y Park; Brandon K Harvey Journal: FEBS J Date: 2017-11-08 Impact factor: 5.542